So lets look at the $1B (assume it is AUD)
Relyvrio sales in 2023 were est at USD$380M <> AUD$587M
Relyvrio is ONLY available in the USA <> Monepantel seeking AU, EU, USA
Relyvrio had numerous customers drop off the treatment due to side effects <> Monepantel so far has very few adverse effects/well tolerated to date.
Relyvrio potential to extend life by average of 9 months (now not so true) <> Monepantel potentially double and more than than so the customer base per year increases (not passing away in 9 months, so on the treatment for much longer)
It may well be this statement that the ASX has taken as a please explain. We will see in time. I do think there is sufficient data to explain an AUD $1B potential annual sales but I can also see where the ASX is dubious too. Unlike us, I highly doubt they study the company fundamentals before demanding a please explain.
adreamer
So lets look at the $1B (assume it is AUD) Relyvrio sales in...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.26M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $119.0K | 679.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 235714 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 190570 | 5 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.000 ( 2.86 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.0¢ | 17.5¢ | 48353 | ||
| Last updated 15.51pm 24/05/2024 ? | |||||
| PAA (ASX) Chart |